Reconsideration of biallelic inactivation of the VHL tumour suppressor gene in hemangioblastomas of the central nervous system

Journal of Neurology Neurosurgery and Psychiatry

Volumn 70, Issue 5, 2001, Pages 644-648

  Glasker S ^a   Bender, B U ^a   Apel, T W ^a   Van Velthoven, V ^b   Mulligan, L M ^b   Zentner, J ^b   Neumann, H P H ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

DNA methylation; Hemangioblastoma; Tumour suppressor gene; Von Hippel Lindau disease

Indexed keywords

ARTICLE; CHROMOSOME 3P; CLINICAL ARTICLE; GENE INACTIVATION; GENE MUTATION; HEMANGIOBLASTOMA; HETEROZYGOSITY LOSS; HUMAN; PRIORITY JOURNAL; PROTEIN METHYLATION; SINGLE STRAND CONFORMATION POLYMORPHISM; SOUTHERN BLOTTING; TUMOR SUPPRESSOR GENE; VON HIPPEL LINDAU DISEASE;

EID: 0035033789     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.70.5.644     Document Type: Article

References (28)

1. Neumann HP, Lips CJ, Hsia YE, et al. Von Hippel-Lindau syndrome. Brain Pathol 1995;5:181-93.
2. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumour suppressor gene. Science 1993;260:1317-20.
3. Stolle C, Glenn G, Zbar B, et al. Improved detection of germline mutations in the von Hippel-Lindau disease tumour suppressor gene. Hum Mutat 1998;12:417-23.
4. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-5.
5. Ohh M, Yauch RL, Lonergan KM, et al. The von Hippel-Lindau tumour suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 1998;1:959-68.
6. Pause A, Lee S, Lonergan KM, et al. The von Hippel-Lindau tumour suppressor gene is required for cell cycle exit upon serum withdrawal. Proc Natl Acad Sci U S A 1998;95:993-8.
7. Ivanov SV, Kuzmin I, Wei MH, et al. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc Natl Acad Sci U S A 1998;95:12596-601.
8. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Gene: 1999;21:163-7.
9. Baylin SB, Herman JG, Graff JR, et al. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998;72:141-96.
10. Kanno H, Kondo K, Ito S, et al. Somatic mutations of the von Hippel-Lindau tumour suppressor gene in sporadic central nervous system hemangioblastomas. Cancer Res 1994;54:4845-7.
11. Oberstrass J, Reifenberger G, Reifenberger J, et al. Mutation of the Von Hippel-Lindau tumour suppressor gene in capillary haemangioblastomas of the central nervous system. J Pathol 1996;179:151-6.
12. Tse JY, Wong JH, Lo KW, et al. Molecular genetic analysis of the von Hippel-Lindau disease tumour suppressor gene in familial and sporadic cerebellar hemangioblastomas. Am J Clin Pathol 1997;107:459-66.
13. Vortmeyer AO, Gnarra JR, Emmert-Buck MR, et al. von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease. Hum Pathol 1997;28:540-3.
14. Lee JY, Dong SM, Park WS, et al. Loss of heterozygosity and somatic mutations of the VHL tumour suppressor gene in sporadic cerebellar hemangioblastomas. Cancer Res 1998; 58:504-8.
15. Crossey PA, Foster K, Richards FM, et al. Molecular genetic investigations of the mechanism of tumourigenesis in von Hippel-Lindau disease: analysis of allele loss in VHL tumours. Hum Genet 1994;93:53-8.
16. Prowse AH, Webster AR, Richards FM, et al. Somatic inactivation of the VHL gene in Von Hippel-Lindau disease rumours. Am J Hum Genet 1997;60:765-71.
17. Neumann HP. Basic criteria for clinical diagnosis and genetic counselling in von Hippel-Lindau syndrome. Vasa 1987;16:220-6.
18. Böhling T, Plate KH, Haltia M, et al. von Hippel-Lindau disease and capillary haemangioblastoma. In: Kleihues P, Cawenee WK, eds. Pathology and genetics of tumours of the nervous system. 2nd ed. Lyon: International Agency for Research on Cancer, World Health Organization, 2000;14: 223-6.
19. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989.
20. Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994;7:85-90.
21. Budowle B, Chakraborty R, Giusti AM, et al. Analysis of the VNTR locus D1S80 by the PCR followed by high-resolution PAGE. Am J Hum Genet 1991;48:137-44.
22. Glavac D, Neumann HP, Wittke C, et al. Mutations in the VHL tumour suppressor gene and associated lesions in families with von Hippel-Lindau disease from central Europe. Hum Genet. 1996;98:271-80.
23. Jones MH, Yamakawa K, Nakamura Y. Isolation and characterization of 19 dinucleotide repeat polymorphisms on chromosome 3p. Hum Mol Genet 1992;1:131-3.
24. Payne SJ, Richards FM, Maher ER. A PCR generated AccI RFLP in the 3′ untranslated region of the von Hippel-Lindau disease (VHL) tumour suppressor gene. Hum Mol Genet 1994;3:390.
25. Neumann HP, Bender BU. Genotype-phenotype correlations in von Hippel-Lindau disease. J Intern Med 1998;243:541-5.
26. Glasker S, Bender BU, Apel TW, et al. The impact of molecular genetic analysis of the VHL gene in patients with haemangioblastomas of the central nervous system. J Neurol Neurosurg Psychiatry 1999;67:758-62.
27. Clifford SC, Prowse AH, Affara NA, et al. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer 1998;22:200-9.
28. Sekido Y, Bader S, Latif F, et al. Molecular analysis of the von Hippel-Lindau disease tumour suppressor gene in human lung cancer cell lines. Oncogene 1994;9:1599-604.